- Home
- KRRO vs MNPR Comparison
KRRO vs MNPR Comparison
Compare KRRO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- MNPR
- Stock Information
- Founded
- KRRO 2014
- MNPR 2014
- Country
- KRRO United States
- MNPR United States
- Employees
- KRRO N/A
- MNPR N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- KRRO Health Care
- MNPR Health Care
- Exchange
- KRRO Nasdaq
- MNPR Nasdaq
- Market Cap
- KRRO 209.6M
- MNPR 249.5M
- IPO Year
- KRRO 2019
- MNPR 2019
- Fundamental
- Price
- KRRO $11.42
- MNPR $31.73
- Analyst Decision
- KRRO Strong Buy
- MNPR Strong Buy
- Analyst Count
- KRRO 7
- MNPR 5
- Target Price
- KRRO $85.67
- MNPR $59.50
- AVG Volume (30 Days)
- KRRO 89.6K
- MNPR 18.2K
- Earning Date
- KRRO 05-07-2025
- MNPR 05-13-2025
- Dividend Yield
- KRRO N/A
- MNPR N/A
- EPS Growth
- KRRO N/A
- MNPR N/A
- EPS
- KRRO N/A
- MNPR N/A
- Revenue
- KRRO $4,821,000.00
- MNPR N/A
- Revenue This Year
- KRRO $20.96
- MNPR N/A
- Revenue Next Year
- KRRO N/A
- MNPR N/A
- P/E Ratio
- KRRO N/A
- MNPR N/A
- Revenue Growth
- KRRO N/A
- MNPR N/A
- 52 Week Low
- KRRO $11.00
- MNPR $1.72
- 52 Week High
- KRRO $98.00
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- KRRO 34.02
- MNPR 37.28
- Support Level
- KRRO $14.54
- MNPR $34.02
- Resistance Level
- KRRO $16.68
- MNPR $36.82
- Average True Range (ATR)
- KRRO 1.49
- MNPR 3.54
- MACD
- KRRO -0.33
- MNPR -0.71
- Stochastic Oscillator
- KRRO 6.24
- MNPR 27.91
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.